Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Immix Biopharma, Inc.NASDAQ: IMMX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 397.8% from a year ago

Cash & equivalents stood at $79.25M at the end of Q1 FY2026, up 397.8% from a year earlier and down 15.6% from the prior quarter. Over 3 fiscal years it compounded at +91.2% a year.

Context

  • Cash & equivalents amounted to 82.7% of total assets at the end of Q1 FY2026, up 2.7 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +397.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$79.25M-15.6% QoQ
Last fiscal yearDec 2025
$93.93M+431.2% YoY
Year agoMar 2025
$15.92M+397.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+397.8%——
1 year+431.2%——
3-year CAGR+91.2%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
93.93M USD
Year-over-year change
+431.2%
4-year CAGR
+51.9%

Cash & Equivalents vs competitors

How IMMX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +397.8% is the 4th highest of 11, against a peer median of -32.3%.
  • Cash & equivalents amounts to 82.7% of total assets for IMMX, versus a peer median of 40.0%.
IMMX Competitors
Cash & Equivalents for IMMX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M USD+818.2%+56.5%60.3%
ABVXAbivax S.A.Jun 2026€387.99M EUR+536.6%+167.6%83.9%
IMUXImmunic, Inc.Mar 2026$186.63M USD+1204.7%-47.5%98.4%
RCUSArcus Biosciences, Inc.Jun 2026$150M USD-39.5%+2.5%16.2%
IMMXImmix Biopharma, Inc.Mar 2026$79.25M USD+397.8%+91.2%82.7%
IMMPImmutep LimitedDec 2025A$72.75M AUD-1.5%-5.5%49.4%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
NBPNovaBridge BiosciencesDec 2025$30.11M USD-94.0%-78.9%80.8%
CTMXCytomX Therapeutics, Inc.Mar 2026$28.83M USD-39.4%-59.7%8.0%
CLDXCelldex Therapeutics, Inc.Sep 2026$26.95M USD-25.2%-0.6%3.7%
CRDFCardiff Oncology, Inc.Mar 2026$8.54M USD-64.5%+2.2%17.4%
Peer median (excluding IMMX) —-32.3%-3.1%40.0%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents17.64M13.44M17.51M17.68M93.93M
Short-term Investments00006.48M
Net Receivables25.72K255.71K1.17M1.97M0
Inventory00000
Other Current Assets516.19K78.07K44.58K32.27K150.72K
Total Current Assets18.19M14.9M19.79M20.2M101.24M
Property, Plant & Equipment (Net)5.7K3.56K50.18K2.73M3.49M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets(0)6.72K87.23K20.42K114.05K
Total Non-current Assets5.7K10.28K137.41K2.75M3.6M
Total Assets18.19M14.91M19.93M22.95M104.84M
Account Payables142.94K143.07K1.43M5.39M5.44M
Short-term Debt50K0000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities000658.16K0
Total Current Liabilities202.04K1.27M3.72M8.69M10.11M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0475K000
Total Non-current Liabilities0475K01.01M933.63K
Total Liabilities202.04K1.75M3.72M9.7M11.04M
Common Stock1.32K1.4K2K2.76K5.3K
Retained Earnings(29.76M)(37.99M)(53.41M)(75.02M)(104.46M)
Accumulated OCI125.41K87.02K134.67K(1.06K)60.16K
Other Stockholders Equity00000
Minority Interest00(201.74K)00
Total Equity17.99M13.16M16.2M13.25M93.8M
Total Debt50K001.07M1.07M
Net Debt(17.59M)(13.44M)(17.51M)(16.61M)(92.86M)

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.